Compare WING & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WING | CRSP |
|---|---|---|
| Founded | 1994 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 5.6B |
| IPO Year | 2015 | 2016 |
| Metric | WING | CRSP |
|---|---|---|
| Price | $247.30 | $57.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 25 | 19 |
| Target Price | ★ $343.33 | $71.50 |
| AVG Volume (30 Days) | 736.5K | ★ 2.4M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | ★ 79.44 | N/A |
| EPS | ★ 6.14 | N/A |
| Revenue | ★ $682,980,000.00 | $38,337,000.00 |
| Revenue This Year | $13.93 | N/A |
| Revenue Next Year | $17.91 | $723.84 |
| P/E Ratio | $40.30 | ★ N/A |
| Revenue Growth | ★ 15.55 | N/A |
| 52 Week Low | $204.00 | $30.04 |
| 52 Week High | $388.14 | $78.48 |
| Indicator | WING | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 47.90 | 53.77 |
| Support Level | $241.12 | $51.16 |
| Resistance Level | $281.28 | $59.77 |
| Average True Range (ATR) | 13.29 | 3.12 |
| MACD | -0.47 | 1.05 |
| Stochastic Oscillator | 36.84 | 82.81 |
Founded in 1994 in Garland, Texas, Wingstop is a restaurant operator specializing in indulgent bone-in and boneless chicken wings, chicken tenders, fries, and, recently, chicken sandwiches. The firm's footprint has grown quickly since its inception, expanding to 2,932 global stores at the end of the third quarter of 2025. With a 98% franchised model, Wingstop generates the lion's share of its revenue from franchise royalties and advertising fees, with the remainder derived from a small footprint of company-owned stores.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.